

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Non-Hodgkin Lymphoma

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. In the Phase III STARGLO trial, the combination of glofitamab and gemcitabine/oxaliplatin resulted in which of the following outcomes in comparison to rituximab with gemcitabine/oxaliplatin for patients with transplant-ineligible relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL)?
 - a. Inferior overall survival (OS)
 - b. Noninferior OS
 - c. Significantly improved OS
2. A subgroup analysis of progression-free survival (PFS) and OS from the Phase III POLARIX trial suggests that the regimen of polatuzumab vedotin-R-CHP may be more efficacious in which patients with newly diagnosed DLBCL?
 - a. Patients with germinal center B cell-like cell-of-origin subtype
 - b. Patients with activated B-cell-like cell-of-origin subtype
 - c. Patients with bulky disease present
 - d. Patients younger than age 65
3. Which of the following best describes outcomes from the Phase III inMIND trial comparing the triplet combination of tafasitamab with lenalidomide/rituximab (R2) to R2 alone in patients with relapsed/refractory follicular lymphoma?
 - a. PFS was similar in both study arms
 - b. PFS was significantly improved with R2 alone
 - c. PFS was significantly improved with tafasitamab with R2
4. AZD0486 is a bispecific antibody targeting...
 - a. CD3/CD20
 - b. CD3/CD19
 - c. CD3/GPRC5D
 - d. CD4/CD8
5. Which of the following best describes results with lisocabtagene maraleucel in the marginal zone lymphoma cohort of the Phase II TRANSCEND FL trial?
 - a. No improvement in overall response rate (ORR)
 - b. Nonsignificant trend toward improved ORR
 - c. Statistically significant improvement in ORR